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PERKEMBANGAN KANSER PAYU DARA PADA TIKUS DI BAWAH KESAN
PLATLET FAKTOR-4 (PF4) DAN/ ATAU RAPAMAISIN
ABSTRAK
Kanser payu dara merupakan punca utama kematian dalam kalangan wanita di
seluruh dunia. Reseptor steroid seperti Estrogen Receptor (ER) dan Progesteron
Receptor (PR) memainkan peranan penting dalam perkembangan kanser payu dara.
Dalam kajian ini, ER dan PR dipilih sebagai penanda untuk menentukan kehadiran
reseptor steroid kerana perkembangan kanser payu dara bergantung kepada hormon
steroid seperti yang telah dilaporkan dalam kebanyakan kajian terdahulu. Selain itu,
Peroxisome Proliferator Activation Receptor γ (PPARγ), salah satu ahli keluarga
dalam kumpulan reseptor hormon nukleus juga ditentukan kerana ianya berperanan
dalam pembahagian sel tumor. Rapamaisin, sejenis bahan daripada mikrolid bakteria
dan Platelet Faktor-4 (PF4), sejenis kemokin mempunyai ciri-ciri antikanser. Oleh itu,
ianya menarik untuk mengkaji kesan Rapamaisin dan PF4 dalam menghalang
perkembangan kanser payu dara disebabkan oleh kesan hormon. Dalam kajian ini,
kanser payu dara diaruh dengan menggunakan 1-Methyl-1-Nitrosourea (MNU)
dengan dos 70mg/ kg berat badan terhadap 80 ekor tikus betina strain Sparague
Dawley. Pengekspresan gen dan protein untuk ketiga-tiga reseptor ini ditentukan
dengan mengggunakan teknik imunohistokimia dan Real-Time PCR. Hasilnya,
semua tumor payu dara merupakan 100% malignan, mempunyai ciri invasive ductal
carcinoma (IDC) yang kebanyakannya adalah jenis cribriform, papillary and Not
Otherwise Specified (NOS). Perawatan dengan Rapamaisin menunjukkan perencatan
perkembangan tumor dan pengurangan keagresifannya. Walaupun pengekspresan ER,
PR berlebihan, pengaktifan PPARγ boleh mengaruh pembahagian sel tumor dan
xvii
xx
seterusnya menukar fenotip agresif tumor kepada fenotip kurang agresif. Manakala,
perawatan dengan PF4 tidak merencat perkembangan tumor dan juga tidak
menunjukkan pengkspresan yang signifikan bagi ER, PR dan PPARγ. Pengaktifan
kawalaturan bagi ketiga-tiganya dalam perawatan kombinasi menyebabkan tumor
berjaya direncat dan keagresifan tumor berjaya disekat. Ianya dijangka bahawa
Rapamaisin lebih menunjukkan kesan antikanser berbanding PF4. Oleh itu, kajian ini
mencadangkan bahawa Rapamaisin bukanlah penggalak atau sinergi dengan PF4.
Kesimpulannya, Rapamaisin berpotensi dalam memainkan peranan sebagai
antikanser kerana ia menghalang perkembangan tumor dan mengaruh pembezaan sel
tumor melalui pengekspresan yang positif bagi reseptor hormon steroid. Kajian yang
lebih mendalam diperlukan bagi mengkaji pengawalaturan jenis isoform bagi ER
(ERα dan ERβ) dan PR ( PR-A dan PR-B) bagi meningkatkan strategi rawatan
kanser payu dara dengan menggunakan antikanser seperti Rapamaisin.
xviii
xxi
BREAST CANCER DEVELOPMENT IN RATS UNDER THE INFLUENCE
OF PLATELET FACTOR-4 (PF4) AND/ OR RAPAMYCIN
ABSTRACT
Breast cancer is a leading cause of morbidity and mortality among women
worldwide. Steroid hormone receptors such as Estrogen Receptor (ER) and
Progesterone Receptor (PR) play a critical role in breast cancer growth. In this study,
ER and PR were selected as markers for steroid receptor determination due to the
strong association between breast cancer development and the influence of steroid
hormones as demonstrated in many studies. On the other hands, the Peroxisome
Proliferator Activation Receptor γ (PPARγ), a family of nuclear hormone receptor
was also determined as it was a potential effector for tumour cell differentiation.
Rapamycin, a drug from bacteria microlide and Platelet Factor-4 (PF4), a platelet-
derived chemokine have anticancer properties. Therefore, it will be interesting to
analyse the effect of Rapamycin and PF4 in blocking the growth of breast cancer
from responding to hormone stimulation. In this study, invasive mammary carcinoma
was induced with 70mg/kg body weight 1-Methyl-1-Nitrosourea (MNU) in 80 young
female Sprague Dawley rats. The gene and protein expressions of ER, PR and
PPARγ markers were evaluated by using semiquantitative immunohistochemistry
analysis and quantitative real-time PCR assay. Findings from the untreated-control
group demonstrated that all mammary lesions are 100% malignant,
histopathologically characterized with invasive ductal carcinoma (IDC) of three
major type ie. cribriform, papillary and Not Otherwise Spesified (NOS). Rapamycin
treatment showed significant inhibition of mammary tumour progression as well as
reduction of tumour agressiveness. Even though treatment with Rapamycin
xix
xxii
significantly overexpressed ER and PR , activation of PPARγ promotes differentiation of
tumour cells which lead to a more differentiated mammary tumour and consequently
reversing the aggressive phenotype of the lesion. Meanwhile, treatment with PF4 did not
regress tumour growth and consequently showed no significant expression of ER, PR
and PPARγ. Upregulation of all these three markers in combination treatment lead to
significant tumour regression and phenotypically decreased aggressiveness. It was
predicted that Rapamycin predominantly showed anticancer effect rather than PF4. Thus,
present findings suggested that Rapamycin is neither synergistic nor additive with PF4.
It was concluded that Rapamycin is a potent anticancer agent for breast cancer because it
halt tumour growth and thus promote tumour cells differentiation through a positive
expression of hormone receptors analysis. Further study will be needed to analyse the
regulation of ER isoforms ( ERα and ERβ ) and PR isoforms ( PR-A and PR-B) to
improve potential therapeutic strategy in breast cancer treatment through anticancer
effects of Rapamycin.
xx
1CHAPTER 1
INTRODUCTION
1.1 Background of the study
Increased incidences of cancer have been noted worldwide. According to The
International Agency for Research on Cancer (IARC), a total of 14.1 million new
cancer cases were reported in 2013 compared to 12.7 million in 2008. Consequently,
the number of cancer related death also increased from 7.6 million cases to 8.2
million cases within the five years (Ferlay J. et al., 2013). Moreover, In the United
States, the incidence rate of invasive cancer was ranged from 387 to 509 per 100,000
population in 2009 compared to 380 to 511 per 100,000 population in 2010 (Henley
et al., 2014). Among the invasive cancers, breast cancer is commonly related to
women and the most prevalence cancer among women. It was the second disease
commonly diagnose after lung cancer and also known as silent killer to women (522
000 deaths in 2012). Furthermore, according to GLOBOCAN 2012, a new version of
IARC’s online database, the global breast cancer risk also rises sharply as the
frequently diagnosed cancer among women in 140 of 184 countries worldwide
(Ferlay et al., 2013).
In Malaysia, The National Cancer Registry 2007 (NCR) also reported breast
cancer as the first most common cancer among population regardless of sex. There
were 3, 242 female breast cancer cases diagnosed in 2007 among Malaysians with
the highest percentage of occurrence (32.1%) followed by other nine malignancies
1
2such as colorectal (10%), cervix uteri (8%), trachea; bronchus; lung (5.4%), corpus
uteri (4.1%), leukemia (3.2%), lymphoma (3.2%), thyroid (3.0%) and stomach
(2.8%).
Cancer is malignant neoplasm which is critically dependent on the host for
nutrition and blood supply. Some neoplasms require endocrine support such as breast
cancer. Estrogen and Progesterone are steroid hormones; play a major role in
controlling the progression of breast cancer cells. However, both hormones are
activated through the binding to their respective receptors namely Estrogen Receptor
(ER) and Progesterone Receptor (PR). It was reported that up to 75% of breast
cancers express positivity of ER and/ or PR which is marked as prognosis factor
breast cancer therapy. Thus, patients with at least 10% ER positive breast cancer
cells in primary tumour effectively responded to endocrine therapy and had better
survival after relapse (Yamashita et al., 2006). On the other hand, a member of
nuclear hormone receptor superfamily, Proxisome Proliferator Activated Receptor-γ
(PPARγ) also tends to become prognosis factor for cancer therapies. Deficient
expression of PPARγ can be a determinant to breast cancer carcinogenesis (Mueller
et al., 1998; Apostoli et al., 2014). As ER  expression increases, the inverse
relationship between receptor expression and proliferation becomes dysregulated.
Increased ER expression is one of the very earliest changes occurring in the
tumorigenic process to malignant transformation of breast cancer cells. Therefore,
cancer cells progression also depend on several molecular pathways which
dysregulated in cancer cells in order to activate the cell proliferations.
Angiogenesis is defined as the formation of a new vascular network out of pre-
existing vessels (Folkman, 1995; Papetti and Herman, 2002). It plays a pivotal role in
sustaining tumour growth in cancer through the activation of angiogenic and angiostatic
2
3factors such as vascular endothelial growth factor, basic fibroblast growth factor and
platelet-derived growth factor (Boudreau and Myers, 2003). On the other hands, other
stimuli can also regulate angiogenesis in direct or indirect manners such as soluble
growth factors, membrane-bound proteins, cell-matrix and cell-cell interactions (Papetti
and Herman, 2002; Otrock et al., 2007a), hypoxia (Boudreau and Myers, 2003),
inflammation and others (Milkiewicz et al., 2006). Nowadays, inhibition of
angiogenesis is a kind of strategy for cancer treatment, whereas Platelet factor-4 (PF4)
is proven to has anticancer property of angiogenesis inhibition by suppressing
endothelial cell proliferation, migration, angiogenesis and metastasis in vitro and in
vivo (Jouan et al., 1999; Struyf et al., 2007; Verpelli et al., 2010).
Moreover, several findings have ruled out that Rapamycin inhibits tumour
cell growth by blocking tumour cell proliferation and angiogenesis. It also proven to
successfully regress the cancer progression by blocking the cell cycle at S and G1
phase during mitosis and also induced apoptosis in cancer cell (Guba et al., 2002).
Rapamycin exerts its activation through a tyrosine/ kinase protein mammalian Target
of Rapamycin (mTOR) which is one of the key modulator for cell proliferation
(Namba et al., 2006; Sabine et al., 2010).
Nowadays, Tamoxifen and Aromatase Inhibitors become favorable therapies
in hormonal positive breast cancer treatments by halting hormonal activities and
hormone production for cancer cell progression and survival. It is interesting to
discover the anticancer potential of Rapamycin and PF4 toward hormonal activities
in breast cancer. In order to determine gene and protein expression of steroid
receptors in Rapamycin and/or PF4-treated breast cancer, this study was undergone
by using animal model for breast cancer. For in vivo experiments, MNU-induced
mammary carcinoma in rats is the model of choice. The MNU induced mammary
3
4tumours are comparable to human due to the site of origin, hormone dependant and
characterized with malignant and aggressive histological features like human (Russo
and Russo, 2000; Thompson and Singh, 2000).
1.2 Objectives of the study
The general objective of the study is to analyse the expression of steroid
growth receptors i.e ER, PR and PPARγ of MNU induced breast cancer under the
influences of PF4 and/or Rapamycin in animal model.
1.2.1 Specific objectives
The specific objectives of the study are:
1. To analyse histopathological features of MNU induced tumours treated with
Rapamycin and/ or PF4.
2. To analyse protein expression of ER, PR and PPARγ of treated tumours using
immunohistochemistry.
3. To analyse gene expression of ER, PR and PPARγ of treated tumours using
quantitative Real-Time PCR.
4. To correlate expression of ER, PR and PPARγ with aggressiveness of treated
tumours.
4
5CHAPTER 2
LITERATURE REVIEW
2.1 Breast Cancer
2.1.1 The prevalence of breast cancer worldwide
Breast cancer is a common disease in the worldwide. Looking at the world as a
whole, the occurrence rate slightly increases every year and commonest among
women (Jemal et al., 2010; Chen et al., 2013a; Henley et al., 2014). Figure 2.1
shows the incidence of breast cancer worldwide based on world age-standardized
rate per 100, 000 persons in 2012.
Figure 2.1 Estimated breast cancer incidence worldwide in 2012.
(Source: GLOBACON 2012).
5
6According to GLOBACON 2012, breast cancer (1.7 million cases) is the
second common cancer diagnosed after lung cancer (1.8 million cases) from year
2008 to 2012 with a sharp increase for incidence number and mortality rate at 20%
and 14% respectively (Bray et al., 2013). Furthermore, Henley and co-workers also
reported the invasive malignancies among female in the United State is the breast
cancer followed by lung, colorectal, and uterine cancer (Henley et al., 2014).
It was surprising that from year 1990 to 2008, the number of females
burdened with breast cancer in European countries is high among female aged below
than 35 years old. Moreover, they were also detected with high incidence of ductal
carcinomas (Leclere et al., 2013). Ductal carcinoma in situ (DCIS) has became a
relatively common malignancy detected upon diagnosis. According to data from
International Cancer Screening Network (ICSN), based on age-standardized,
detection rates of DCIS varied from 0.41 to 1.38 per 1000 women in Europe, United
State and Japan. The rate varies across the countries as a result of different DCIS
diagnosis and treatment processes (Ponti et al., 2014).
In Asia, for instance, China cancer registry also stated that breast cancer is
one of the top ten common cancers leading to death in age-standardize China
population with mortality rate 5.13 per 100, 000 and frequently diagnosed among
female (incidence rate 42.55 per 100, 000) in year 2009 (Chen et al., 2013a).
2.1.2 Breast cancer risks in Malaysia
In Malaysia, the exact causes for breast cancer risks are still unknown.
However, several risk factors increase the chance of getting this disease were
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7categorized by uncontrollable and controllable factors. Briefly, the uncontrollable
factors are family history and age, whereas the controllable factors are breast feeding,
food intake, alcohol intake, smoking habits and physical exercises (Baqutayan et al.,
2012)
As shown in Figure 2.2, The National Cancer Registry 2007 has reported that
breast cancer (18.1%) is the most frequent diagnosed cancer among the Malaysian
compared to colorectal (12.3%), trachea, bronchus, lung (10.2%), nasopharynx
(5.2%) ,cervix uteri (4.6%), lymphoma (4.3%), leukemia (4.1%), ovary (3.6%),
stomach (3.5%) and liver (3.3%). Moreover, Malaysian females are suffering from
breast cancer more than other cancers (Figure 2.3) and it was estimated that one in
twenty women in the country developed breast cancer in their lifetime. Among them,
Chinese women are commonly diagnosed with this disease followed by Indians and
Malay (Baqutayan et al., 2012) as the effect of different culture and lifestyle.
Ironically, their overall survival rate was lower than Western, especially Malay
women due to delaying for diagnosis and treatment at hospital; after a long period of
symptom, presented at the late stage, had larger tumour size and more lymph nodes
affected (Ibrahim et al., 2012; Abdullah et al., 2013). Therefore, it is important to
promote breast cancer screening in all Malaysian women for early detection and
treatment in order to reduce the number of breast cancer fatality and disease burden
in Malaysia. Consequently, many breast cancer prevention and control programs are
implemented by the government to improve breast health in our country includes
encouraging breast self examination in all women, free mammogram screening in
government hospital and a RM50 subsidy for every mammogram done in private
clinics and hospitals registered with the National Population and Family
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8Development Board Malaysia (NPFDB) for those who are burdened with high risk of
breast cancer (Dahlui et al., 2011).
Figure 2.2 The percentage of ten most frequent cancer diagnosed among Malaysian
in 2007. (Omar and Ibrahim Tamim, 2011)
Figure 2.3 Percentage of ten most frequent cancer detected in Malaysian female in
2007 (Omar and Ibrahim Tamim, 2011)
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92.2 MNU induced breast cancer animal model
Animal model systems provide invaluable tools in understanding the
complexity of multistep carcinogenesis. For decades, the animal model for breast
cancer has been used widely in breast cancer prevention and treatment, as its
malignancy progression depends on the hormonal status and histopathologically
similar to human. Moreover, there are several availability of known initiating agents
potentially promotes breast carcinogenesis, such as viral induction, ionizing radiation
and chemical carcinogens such as 1-methyl-1-nitrosourea (MNU), 7,12-
dimethylbenz[a]anthracene (DMBA), and 2-amino-1-methyl-6-phenylimidazo[4,5
b]pyridine (PhIP) (Russo and Russo, 2000; Imaoka et al., 2014).
MNU-induced mammary carcinoma model has been widely used in the
investigation of novel breast cancer chemoprevention and therapeutic. Many
extensive informations were available, characterizing pathogenesis of tumour growth
associated with this compound (Gusterson and Williams, 1981; Thompson and
Adlakha, 1991; Thompson and Singh, 2000; Esendagli et al., 2009). MNU induced
mammary tumourigensis in a dose-dependent manner as high MNU dosage increased
the tumour multiplicity, shortened the latency period and produced more malignant
tumour than benign (Thompson and Adlakha, 1991; Thompson et al., 1992). In
addition, the carcinomas induced by MNU were ovarian hormone dependence in
carcinogenic initiation and tumour progression (Thompson et al., 1998a).
Furthermore, the injection of sexually immature female rats with MNU
results in a rapid induction of premalignant and malignant mammary gland lesions. It
was proven that the mammary tumour was palpable post 35 days MNU
administration with 50 mg MNU/ kg body weight at 21 days of age (Thompson et al.,
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1995). The young mammary gland was more susceptible to carcinogenesis. In
younger rats, the terminal end buds (TEB) are not well differentiated and frequently
mitosis. It is comprised of intermediate cells, myoepithelial cells and have a single
lumen with a smooth border. Tumours arise from ductal epithelial cells as in most
human breast carcinomas (Thompson and Singh, 2000; Thompson et al., 2000);
whereby the early lesions, called intraductal proliferations (IDP) formed after MNU
administration (Thompson et al., 1998b). It was the earliest change observed in
mammary parenchyma as the dilation of TEB occurs. The epithelial lining thickening
up to six layers thick and the cells have a large, round nucleus, prominent nucleolus,
and coarse chromatin along the inner leaflet of the nuclear membrane. Recently, in
year 2011, Sharma et. al had disclosed the cellular differentiation profile of the
MNU-induced rat mammary epithelial cells by quantitative protein expression of the
luminal and basal myoepithelial populations (Sharma et al., 2011). The results
enhanced rat mammary carcinogenesis model in the study of the role of epithelial
cell differentiation in breast cancer.
The epithelial derived mammary neoplasm are predominantly characterized
with in situ ductal carcinoma (DCIS) and invasive carcinoma of papillary, cribriform
and comedo type (Russo and Russo, 2000). Neoplastic transformation of mammary
epithelial cells in MNU-induced rats is associated with decrease apoptosis in the
lesions (Shilkaitis et al., 2000). Thus, histopathological features of tumour is
important because those characteristics have implications for the interpretation of
experimental mammary carcinoma in animal.
The pathogenetic characteristics of this experimental model of breast cancer
are being defined with the use of molecular techniques, such as an identifiable
somatic genetic changes GGA-to-GAA transition in codon 12 of the Ha-ras gene is
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highly prevalent in MNU-induced rat mammary carcinoma (Lu et al., 1998; Imaoka
et al., 2014). The mechanism of initiation of genetic mutation by MNU began when
MNU generates O-6-methylguanine, which then base-paired with cytosine and
thymidine, leading to a G-to-A transition upon subsequent DNA replication.
However, Ha-Ras gene mutation by MNU is inversely proportion to the MNU
dosages (Lu et al., 1998; Thompson et al., 2000).
2.3 Anticancer properties of Platelet Factor-4 (PF4)
The CXC-chemokines involve in biological activities such as modulation of
inflammation, hemostasis and angiogenesis. Chemokines are cytokines which recruit
leukocytes to inflammatory sites, acting as growth factor in tumour development and
metastasis and influencing angiogenesis. Platelet Factor 4 (PF4) also known as
CXC4 chemokine, a potentially chemokine shown to act as anticancer by inhibiting
angiogenesis (Maione et al., 1990; Struyf et al., 2007) and promoting apoptosis
(Liang et al., 2013; Din et al., 2014).
PF4 is a product of platelet release reaction, a tetrameric molecule with low
molecular weight composed of 70 polypeptide residues. The peptide between amino
acids 47 and 70 posses heparin-binding lysine-rich site which play an important role
in angiogenesis, especially in the four sites of lysine 61, 62, 65 and 66 which are
found on a single α-helix on each PF4 monomer. This heparin binding site located at
the carboxyl (COOH) terminal end and positively charged. Meanwhile, the other
amino (NH2) terminal is highly acidic and negatively charged (Deuel et al., 1977;
Jouan et al., 1999; Bikfalvi, 2004). Majority of the NH2 terminal contains three
amino acid residues (Glutamine -Leusine- Arginine) named as ELR motif (Belperio
et al., 2000). The existence of this motif is also a prediction of pathological features
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of CXC chemokine where ELR-positive is potent angiogenesis promoter whilst
ELR- negative is potent inhibitor of angiogenesis. The ELR+ CXC chemokines
including: CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8.
Meanwhile, ELR- CXC chemokines are subdivided into two types: angiostatic ELR-
CXC chemokines CXCL4, CXCL4L1 and CXCL14 and Interferon-inducible ELR-
CXC chemokines CXCL9, CXCL10, and CXCL11 (Strieter et al., 2004; Keeley et
al., 2008). The CXCL4L1, a PF4 variant was successfully inhibited angiogenesis in
melanoma and lung carcinoma growth and metastasis in vivo (Struyf et al., 2007).
The angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 are
mediated by CXCR3 (Struyf et al., 2011). In addition, CXCL4’s capacity in
inhibiting angiogenesis and promoting immune response had become a tool and
target for potential intervention in tumor growth and inflammation with more
emphasis on molecular pathways and mechanism of action of PF4 (Kasper and
Petersen, 2011).
The mechanism of PF4 inhibition of angiogenesis had been tested as single
agents in clinical trials (Hawkins, 1995) whereby the concept of antiangiogenesis
therapy was proposed in early 1970s (Folkman and Ingber, 1992). They summarized
three strategies for antiangiogenesis; inhibition of release of angiogenic molecules
from tumour cells, neutralization of released angiogenic molecule and blocking the
vascular endothelial cells from responding to angiogenic stimulation. On the other
hand, PF4 blocks the binding of vascular endothelial growth factor (VEGF) and
fibroblast growth factor-2 (FGF2) to cell surface heparan sulfates which both
modulated by heparan sulfateproteoglycans (HSPGs) to their respective receptors
during angiogenesis. The heparin binding prevents endothelial cell proliferation,
migration and differentiation. In addition, heparin reduces the activation and effects
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of matrix metalloproteinases, serine proteases, and heparanases in promoting
metastasis (Engelberg, 1999).
PF4 also inhibited cancer cells growth by inducing apoptosis in myeloma
cells through a negative regulation of signal-transducer-and-activator-of-
transcription-3 (STAT3) in vitro and in vivo (Liang et al., 2013). STAT3 is known
to regulate proliferation, apoptosis and angiogenesis in multiple myeloma cells
through regulating the expression of its target genes including c-Myc, Bcl-XL, Bcl-2,
Survivin and VEGF. This was positively correlated with a study by Din et. al in 2014
who proved that the treatment of PF4 successfully caused overexpression of pro-
apoptotic protein Bax and regression of Survivin protein expression in rat mammary
carcinoma (Din et al., 2014).
2.4 Rapamycin inhibits cancer cell growth
Rapamycin (sirolimus) is a substance extracted from bacteria macrolide of
Streptomyces hygroscopicus found in the soil of Easter Island, Rapa Nui. It was
originally used as antifungal, antibacterial and an immunosuppresion agent in kidney
transplantation. However, recently scientists discovered its anticancer activity, which
leads to several test that came into phase II clinical trial as anticancer agent. The
chemical structure of Rapamycin (sirolimus) as shown in Figure 2.5.
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Figure 2.4 The chemical structure of sirolimus (Yardley, 2013)
Several mTOR inhibitors have been developed and evaluated as antitumor
therapies, with some distinctive differences in metabolism, formulation, and schedule of
administration. Sirolimus is the major metabolite of CCI-779 (a Rapamycin analogue)
(Chan, 2004). Another analogues of sirolimus which are demonstrated to have more
favorable pharmacokinetics include temsirolimus, everolimus and ridaforolimus.
Sirolimus has been approved for renal transplant injection in 1999 and entered phase
2 and 3 in clinical trials. Meanwhile temsirolimus had been approved for advanced
renal cell carcinoma in 2007 as well as everolimus, which is also presently approved
for renal angiomyolipoma and tuberous sclerosis in 2012. Besides, radifolimus has
been entered phase 3 in clinical trial (Yardley, 2013).
Growth inhibition was associated with reduction of cell proliferation and
angiogenesis with promotion of apoptosis. Therefore, Rapamycin potentially induced
phenotypic transition from invasive spindle, or dome-shaped cells, with exploratory
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pseudopodia to noninvasive cuboidal cells that formed cell-to-cell adhesions of renal
cancer cells (Luan et al., 2002) and breast cancer cell line proliferation, growth and
apoptosis in vitro (Noh et al., 2004; Kasukabe et al., 2005; Chang et al., 2007).
Moreover, in vivo treatment with Rapamycin reduced the aggressiveness of invasive
renal and bladder cancer cells, inhibited the growth of MCF-7 cells as xenografts
and ductal carcinoma in situ malignancy in mouse model (Luan et al., 2002;
Kasukabe et al., 2005; Namba et al., 2006).
Mammalian target of rapamycin (mTOR) is a 289-kDa serine/ threonine
kinase protein that integrates multiple signals from growth factors and hormones and
plays a central role in the control of cell growth, proliferation, and angiogenesis. It
was a downstream target of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
Activation of PI3K/Akt/mTOR mediates multiple cellular functions to tumour
initiation, progression and survival (McAuliffe et al., 2010).
The Rapamycin has affinity to bind to mTOR protein and consequently
caused inactivation of mTOR downstream target. Thus, Rapamycin is also
recognized as mTOR inhibitor. In preclinical breast cancer models using MCF-7 cells
with constitutively active Akt/mTOR that exhibit hormone and chemotherapy resistance,
dual inhibiton of PI3K and mTOR inhibitors enhanced the efficacy of selective ER
modulator tamoxifen in breast cancer (Chen et al., 2013b). The summary of mechanism
of mTOR inhibition in cancer cells is shown in Figure 2.5.
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Figure 2.5 The PI3K/Akt/mTOR pathway. Abbrevations: 4E-BPs, 4 eukaryotic
binding proteins; EIF4K, eukaryotic initiation factor 4K; mTORC, mammalian target
of rapamycin complex; PTEN, phosphatase and tensin homolog; S6K1, ribosomal
protein S6 kinase 1; S6, ribosomal protein S6; TSC1, tuberous sclerosis complex1;
TSC2, tuberous sclerosis complex 2; PI3K, phosphoinositide 3-kinase; EGFR,
epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2;
IGF-1R, insulin growth factor 1; Akt/PKB, protein kinase B; AMPK, AMP-activated
protein kinase; LKB1, liver kinase B1; ILK, integrin-linked kinase (Lane and
Lebwohl, 2006).
2.5 Regulation of Estrogen Receptor in Breast Cancer
Cell proliferation, differentiation, apoptosis, and cell motility are promoted and
regulated by several factors such as growth factors and hormones (Sherbet, 2005).
The hormones related cancer such breast cancer shared different mechanism of
carcinogenesis by driving cell proliferation, increase the number of cell division and
opportunity for random genetic errors. Meanwhile, breast cancer risk is associated
with prolonged exposure to female hormones such as estrogen which is either of
ovarian or extra-ovarian origin. It was proven in vivo that the tumorigenic response
is maximal when the carcinogen is administered to young and virgin intact animals in
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which the mammary gland is undifferentiated and highly proliferating (Thompson et
al., 1995; Thompson et al., 1998a). Increased proliferation could result in turn in
accumulation of genetic damage and stimulation of the synthesis of growth factors
that act on the mammary epithelial cells via an autocrine or paracrine loop (Russo
and Russo, 1998).
Estrogen had clearly been shown to play a critical role in regulation of growth
and differentiation of the normal mammary gland and mammary malignancy. Its
Estrogenic activity in cells is mediated by high affinity binding protein receptor
namely Estrogen Receptor (ER). Estrogen has direct mitogenic effects and promote
paracrine mediators of estrogen action in mammary gland upon positivity of ER in
mammary epithelial cell. Moreover, it was proven that ER is co-expressed with the
proliferation antigen Ki67 in a population of normal primate mammary epithelial
cells (Dimitrakakis et al., 2006). ER expression could be a determinant of estrogen
action in other tissues such as uterus and ovary. Studies of the ER expression and
function in cancer are very important in improving the new strategies of prevention,
diagnosis and therapy in estrogen-dependant cancers (Hayashi et al., 2003).
Therefore, ER expression is considered as prognosis factor in cancer therapy
especially breast cancer.
There are two types of ER which distinctly regulated breast cancer
progression. ERα and ERβ (as shown in Figure 2. 6) are the products of two separate
genes that are differentially expressed in tissues. ERα is 66kD receptor protein
located in cytoplasm and nucleus of cells which is responsible for estrogen-induced
mitogenic signaling in epithelial cells in breast, uterine and ovarian tissues.
Meanwhile, ERβ, 36kD protein located in cytoplasm and functionally controls cell
proliferation and differentiation. Both ER isoforms are expressed at similarly low
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levels in the normal breast, whereas ERα is predominantly expressed at high level
rather than ERβ in breast cancer cells. Thus, the expression of ERβ is downregulated
in lesions such as atypical ductal hyperplasia and DCIS compared with that in
normal breast epithelium, as it is inversely correlated with proliferation. This is
consistent with the suggestion that the ERβ negatively modulates the effects of the
ERα (Roger P. et al., 2001).
Figure 2.6 Structure of estrogen receptor (ER) and progesterone receptor (PR). ER
consists of two isoforms ERα and ERβ that are transcribed from two genes. PR also
consists of two isoforms PRA and PRB that are transcribed from a single gene using
an alternative promoter and translation start site. Abbreviations: DBD, DNA-binding
domain; LBD, ligand-binding domain. (Cui et al., 2005).
In breast cancer treatment therapy, ER status has been used clinically almost
40 decades to identify those patients most likely to benefit endocrine therapies
through its signaling pathway (Muscat et al., 2013; Renoir et al., 2013; Palmieri et
al., 2014). It has been a central to management in breast cancer as a prognosis factor
acts as a guide to treatment (Osborne et al., 1980). ERs are activated by two general
mechanisms ligand dependent activation (the classic pathway or genomic pathway),
in which estrogen binds to the ER and the resulting estrogen-ER unit then interacts
directly with DNA to regulate gene transcription; and ligand independent activation
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(non classical pathway or nongenomic pathway), in which an ER is activated, in part,
after phosphorylation by growth factor receptors or other molecules with serine or
tyrosine kinase domains. This pathway plays a central role in breast cancer
development including cell survival, proliferation, and angiogenesis (Hasson et al.,
2013). Briefly, the summary of genomic and non-genomic ER signaling pathway is
shown in Figure 2.7.
Figure 2.7 Genomic and nongenomic ER pathway in estrogen receptor (ER)-positive
tumor cells. (Pietras and Marquez-Garban, 2007)
2.6 Regulation of Progesterone receptor in Breast Cancer
Progesterone is a critical regulator of normal female reproductive function, with
diverse tissue-specific effects in the human. The effects of progesterone are mediated
by its nuclear receptor (PR); a member of a large family of ligand-activated nuclear
transcription regulators. The structure PR was described previously in Figure 2.6.
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PR is expressed as two isoforms, PRA and PRB. Both are identical in
sequence, except that PRA lacks 164 amino acids at the N-terminus, making it the
shorter of the two proteins. In human physiology, the majority of PR positive cells
express PRA and PRB at equivalent levels (Mote et al., 2002; Mote et al., 2007).
In vivo study demonstrated PR was important in development of alveoli. PR
mediated the binding of progesterone then activated the ductal cells. Upon the
crosstalk with the stroma, a signal was passed directly to the alveolar precursor cells.
Mammary epithelial cells which lack of PR had a failure in side branching (Brisken
et al., 1998). The presence of PR in tumour is also an important predictor of tumour
aggressiveness and responsiveness to endocrine therapy. Progesterone receptor has
provided a mean in hormonal therapy in breast cancer therapeutics. Both ER/PR +ve
and ER+ve/ PR- breast cancer sub typing are responsive to hormonal therapy;
however the present of PR+ve enhanced the effectiveness of treatment (Bloom et al.,
1980; Osborne et al., 1980; Bardou et al., 2003) Thus the status of ER and PR
appears as a prognostic index in the patient selection for the therapy.
2.7 Regulation of Peroxisome Proliferator Activation Receptorγ in Breast
Cancer Cells.
The peroxisome proliferator-activated receptors (PPARs) are a group of ligand-
activated transcription factors which belong to the nuclear hormone receptor
superfamily proteins. PPARs play essential roles in the regulation of carbohydrate,
lipid, protein metabolism, cellular differentiation, development, and tumorigenesis.
There are three types of PPARs namely PPAR alpha (PPARα), PPAR beta/
delta (PPARδ/ PPARβ) and PPAR gamma (PPARγ) (Roberts-Thomson, 2000).
Among the three PPARs subunit, PPARγ plays a critical role in regulating
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tumourigenesis. In general, PPARγ can be found in adipose tissue, colonic epithelia,
macrophages, endothelium, small intestine , liver, breast and others. The high
expression of PPARγ and its RXRα ligand showed activation of this heterodimers
potentially induce cell death in transitional bladder cancer (Guan et al., 1999).
Furthermore, there was an evidence that a cross-talk between ER and PPARγ by
reciprocal interaction between PPARγ and ERβ significantly inhibits the proliferation
and migration of thyroid cancer cells (Chu et al., 2014).
In breast cancer, activation of PPARγ by respective ligand promotes terminal
differentiation of the cancer cells (Mueller et al., 1998); caused dramatic
morphological and molecular changes to a less malignant state and well
differentiated cells. For instance, a pilot study by (Yee et al., 2007) disclosed the
activation of short-term rosiglitazone therapy in early-stage breast cancer patients
leads to local and systemic effects on PPARγ signaling in inhibiting tumour growth
and progression in human breast cancer. Meanwhile, estrogen biosynthesis in human
breast adipose tissues also successfully inhibited by PPARγ ligands activity,
suggesting as possible implication in breast cancer therapy (Rubin et al., 2000).
Moreover, upregulation of BRCA1 and decreasing leptin secretion by activation of
PPARγ in mammary stromal adipocytes regressed mammary tumourigenesis in vivo
(Skelhorne-Gross et al., 2012). PPARγ ligands also induced apoptosis and
antiproliferation in human breast cancer cell lines (Crowe and Chandraratna, 2004;
Lea et al., 2004).
PPARγ activation mechanism involved the Retinoid-X-Receptor (RXR) and
PPARγ Element (PPRE). The heterodimer of PPARγ and RXRα interacts with co-
regulators. Binding of specific PPARγ ligand leads to coactivator recruitment and
corepressor release. Upon the activation, PPARγ/ RXRα heterodimer binds to the
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PPRE which is present in the promoters of target genes and activate gene
transcription. Figure 2.8 shows the mechanism of PPARγ signaling.
Figure 2.8 Schematic diagram of PPARγ signaling. Abbreviations: PPARγ:
Peroxisome Proliferated Activation gamma; RXRα: Retinoid-X-Receptor alpha;
DBD: DNA Binding Domain; RNA: Ribonucleic Acid. (Rumi et al., 2004).
2.8 Histological grades in breast cancer
The purpose of breast cancer classification is to select the best treatment. Breast
cancer can be classified based on tumour grade, tumour stage and histological type,
receptor status and DNA testing of certain genes.
Grading focuses on the appearance of the breast cancer cells compared to the
appearance of normal breast tissue. Cancerous cells are not well differentiated
compared the normal cells which take on specific shapes and forms that reflect their
function as part of that organ. In cancer, the breast cells become disorganized, cell
division becomes uncontrolled and cell nuclei become less uniform. Poorly
differentiated cancers have a worse prognosis. The Nottingham also called Elston-
Ellis modification of the Scarff-Bloom-Richardson grading system is a grading
system currently adopted by World Health Organisation (WHO) (Genestie et al.,
1998). This system grades breast carcinomas based on three parameters such as
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tubule formation (how much of the tumour tissue has normal breast milk duct
structures), nuclear pleomorphism (an evaluation of the size and shape of the nucleus
in the tumor cells) and mitotic count (how many dividing cells are present, which is
a measure of how fast the tumor cells are growing and dividing) respectively. These
features were given 1 to 3 points each which is then added together to give an overall
final score of 3 to 9. Tumour grade 3-5 represent well-differentiated cells have best
prognosis compared grade 6-7 and 8-9 which represent moderate differentiated and
poorly differentiated respectively. Therefore, lower-grade tumors, with a more
favorable prognosis, can be treated less aggressively, and have a better survival rate
(Bloom and Richardson, 1957; Elston and Ellis, 1991).
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CHAPTER 3
MATERIALS AND METHODS
3.1 Study design
This in vivo study involving induction of mammary tumourigenesis in rat by
a carcinogen, followed by histological features classification and determination of
the effectiveness of anticancer agents through the steroid receptor analysis.
Throughout this study, 1-Methyl-1-Nitrosourea (MNU) was intervened into
the female Sparague Dawley rats at the dose of 70mg/kg body weight to promote
mammary tumour formation (Jaafar et al., 2009). The tumors were divided into
control and treatment groups. Treatment interventions of Rapamycin, Platelet-Factor-
4 (PF4) and combination of Rapamycin and PF4 were done when tumour diameter
size reached 14.5 ± 0.5 mm. Tumours regression was observed after 5 days of
treatment interventions. Both anticancer agents were chosen based on their ability
to inhibit cancer progression through anticancer properties towards cancer cells.
All tumour tissues were subjected to histopathological analysis and steroid
receptor analysis. The expressions of Estrogen Receptor, Progesterone Receptor and
Peroxisome Proliferator Activation Receptor-γ (PPAR-γ) were determined by
semiquantitative protein expression of Immunohistochemistry and quantitative gene
expression of Real-Time Polymerase Chain Reaction (RT-PCR) assays. Statistical
inferences were then performed to justify the results. The study design was
summarized as shown in Figure 3.1.
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